Astrazeneca Scores Milestone Victory In Oncology

Astrazeneca Scores Milestone Victory In Oncology


AstraZeneca stock was treading water on Friday despite the pharma titan receiving full approval from the U.S. Food and Drug Administration for a key drug within its oncology portfolio and announcing a licensing deal over another cancer treatment. The FDA granted Tagrisso 80mg once-daily tablets full approval for treatment of a T790M mutation-positive non-small cell lung cancer , after it was found superior than the one other available treatment - chemotherapy - for the condition.



from Biotech News